Blood thinner may protect cancer patients from potentially fatal clots

June 7, 2011

A new type of anti-clotting drug called semuloparin has been found to reduce the development of potentially fatal blood clots in the veins that often occur in cancer patients, doctors at Duke Cancer Institute and elsewhere reported today.

In a large phase III clinical trial involving 3,212 , semuloparin provided a 64 percent reduction in the risk of venous thromboembolism (VTE), the blockage of an artery, compared to placebo, the study's authors reported at the 2011 annual meeting of the American Society of Clinical Oncology.

" is a leading cause of death among cancer patients," said Daniel George, MD, director of genitourinary medical oncology at Duke University Medical Center and one of the study authors. "But we don't do much to prevent these events. We need interventions to reduce this risk of complication."

The drug, an ultra-low-weight manufactured by Sanofi, had previously shown benefit in preventing blood clots among orthopaedic , who tend to develop VTEs from lengthy recuperations that keep them from being active.

Among cancer patients, though, VTEs appear to stem from a link between tumor biology and processes that cause blood to coagulate. Studies have shown that patients with cancer have nearly a six-fold increased risk of VTE compared with non-cancer patients, accounting for about 20 percent of all new VTE events. Chemotherapy use further increases this risk.

Currently, are offered to cancer patients when a clot is discovered, either as a or pulmonary embolism; the clots can be deadly when they dislodge and travel to the lungs.

The study -- which was sponsored by the drug's manufacturer, Sanofi -- tested the use of semuloparin as a way to prevent VTEs, not just treat them after the fact. That approach could change how doctors practice.

In the study, half the cancer patients were randomly assigned to receive the new drug in addition to their chemotherapy, and the other half got a placebo during their normal treatments.

Twenty of 1,608 patients who received the blood thinning drug had VTE events (1.2 percent), while 55 of 1,604 patients in the placebo group developed clots (3.4 percent).

"These data support a shift in our practice toward actively preventing this disease rather than waiting for symptoms," George said.

George said one concern about adding anti-coagulant drugs to current cancer treatments is that patients could develop serious bleeding problems. Patients in the trial, however, did not have higher rates of those complications.

"The safety profile is reassuring," George said.

George serves as a consultant for and receives honoraria from Sanofi.

Related Stories

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.